MA26989A1 - Derives de pyridine inhibiteurs de metalloproteinases de matrice - Google Patents
Derives de pyridine inhibiteurs de metalloproteinases de matriceInfo
- Publication number
- MA26989A1 MA26989A1 MA27263A MA27263A MA26989A1 MA 26989 A1 MA26989 A1 MA 26989A1 MA 27263 A MA27263 A MA 27263A MA 27263 A MA27263 A MA 27263A MA 26989 A1 MA26989 A1 MA 26989A1
- Authority
- MA
- Morocco
- Prior art keywords
- pyridine derivatives
- independently represent
- alkynyl
- alkenyl
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
DEPOSANT Société dite : WARNER-LAMBERT COMPANY LLC REVENDICATION DE PRIORITES US 14 Février 2001 60/268,781 Voir en annexe le titre de l'invention et le texte de l'abrégé Dérivés de pyridine inhibiteurs de métalloprotéinases de matrice Des inhibiteurs sélectifs de MMP-13 sont des dérivés de pyridine de formule (I) ou un de leurs sels pharmaceutiquement acceptables, formule dans laquelle : R1 et R2 représentent indépendamment un atome d'hydrogène, un groupe halogéno, hydroxy, alkyle en C1 à C6, alkoxy en C1 à C6, alcényle en C2 à C6, alcynyle en C2 à C6, NO2, NR4R5, CN ou CF3 ; E représente indépendamment un atome de O ou S ; A et B représentent indépendamment un groupe OR4 ou NR4R5 ; R4 et R5 représentent indépendamment H, un groupe alkyle en C1 à C6, alcényle en C2 à C6, alcynyle en C2 à C6, (CH2)n-aryle, (CH2)n-cycloalkyle ou (CH2)n-hétéroaryle, ou bien R4 et R5, lorsqu'ils sont pris conjointement avec l'atome d'azote auquel ils sont fixés, complètent un noyau tri- à octogonal, contenant des atomes de carbone et contenant facultativement un hétéroatome choisi entre O, S et NH, facultativement substitué ou non substitué ; n a une valeur de 0 à 6.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26878101P | 2001-02-14 | 2001-02-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA26989A1 true MA26989A1 (fr) | 2004-12-20 |
Family
ID=23024446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA27263A MA26989A1 (fr) | 2001-02-14 | 2003-08-05 | Derives de pyridine inhibiteurs de metalloproteinases de matrice |
Country Status (36)
Country | Link |
---|---|
US (2) | US6881743B2 (fr) |
EP (1) | EP1362033B1 (fr) |
JP (1) | JP4249981B2 (fr) |
KR (1) | KR20030075196A (fr) |
CN (1) | CN1537101A (fr) |
AP (1) | AP2003002840A0 (fr) |
AR (1) | AR035936A1 (fr) |
AT (1) | ATE358667T1 (fr) |
BG (1) | BG108089A (fr) |
BR (1) | BR0207863A (fr) |
CA (1) | CA2434982A1 (fr) |
CR (1) | CR7048A (fr) |
CZ (1) | CZ20032143A3 (fr) |
DE (1) | DE60219286T2 (fr) |
DO (1) | DOP2002000332A (fr) |
EA (1) | EA200300763A1 (fr) |
EC (1) | ECSP034691A (fr) |
EE (1) | EE200300391A (fr) |
ES (1) | ES2283540T3 (fr) |
GT (1) | GT200200014A (fr) |
HN (2) | HN2002000028A (fr) |
HU (1) | HUP0303152A2 (fr) |
IL (1) | IL156912A0 (fr) |
IS (1) | IS6871A (fr) |
MA (1) | MA26989A1 (fr) |
MX (1) | MXPA03006204A (fr) |
NO (1) | NO20033570L (fr) |
OA (1) | OA12544A (fr) |
PA (1) | PA8538201A1 (fr) |
PE (1) | PE20020995A1 (fr) |
PL (1) | PL365098A1 (fr) |
SK (1) | SK10022003A3 (fr) |
TN (1) | TNSN02012A1 (fr) |
UY (1) | UY27167A1 (fr) |
WO (1) | WO2002064568A1 (fr) |
ZA (1) | ZA200306041B (fr) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DOP2002000333A (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz |
DOP2002000328A (es) | 2001-02-14 | 2003-08-30 | Warner Lambert Co | Pirimidinas inhibidoras de metaloproteinasas de matriz |
US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
JP4164028B2 (ja) | 2001-10-12 | 2008-10-08 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | アルキンマトリックスメタロプロテイナーゼ阻害剤 |
DE10160357A1 (de) * | 2001-12-08 | 2003-06-18 | Aventis Pharma Gmbh | Verwendung von Pyridin-2,4-dicarbonsäurediamiden und Pyrimidin-4,6-dicarbonsäurediamiden zur selektiven Inhibierung von Kollagenasen |
US6933298B2 (en) | 2001-12-08 | 2005-08-23 | Aventis Pharma Deutschland Gmbh | Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases |
US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US20040006077A1 (en) * | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
CA2495432A1 (fr) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combinaison d'un inhibiteur carboxylique allosterique de metalloproteinase-13 de matrice et de celecoxibe ou de valdecoxibe |
BR0312943A (pt) * | 2002-07-17 | 2005-07-12 | Warner Lambert Co | Combinação de um inibidor alostérico de matriz metaloproteinase-13 com um inibidor seletivo de ciclooxigenase-2 que não é celecoxib ou valdecoxib |
CA2492379A1 (fr) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combinaison d'un inhibiteur allosterique de la metalloproteinase matricielle 13 avec un celecoxib ou valdecoxib |
WO2004006914A1 (fr) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combinaison d'un inhibiteur alcyne allosterique de la metalloprotease matricielle-13 et de celecoxib ou de valdecoxib |
AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
EP1537090A1 (fr) | 2002-08-13 | 2005-06-08 | Warner-Lambert Company Llc | Derives de chromone inhibiteurs de metalloproteinase de matrice |
ES2283851T3 (es) | 2002-08-13 | 2007-11-01 | Warner-Lambert Company Llc | Derivados de pirimidin-2,4-diona como inhibidores de las metaloproteinasas de matriz. |
AU2003249477A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
AU2003250466A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
EP1530472A1 (fr) * | 2002-08-13 | 2005-05-18 | Warner-Lambert Company LLC | Derives d'isoquinoleine utilises comme inhibiteurs de metalloprotease de matrice |
AU2003250470A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
WO2004014365A1 (fr) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Derives de phtalimide inhibiteurs de metalloproteinase de matrice |
WO2004014916A1 (fr) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Inhibiteurs bicycliques condenses de metalloproteinases de type pyrimidine |
PA8578101A1 (es) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
AU2003249531A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
WO2004014909A1 (fr) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Derives fusionnes de la tetrahydropyridine inhibiteurs de la metalloprotease matricielle |
AU2003249535A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
AU2003249539A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
AU2003250475A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
JP2006501215A (ja) | 2002-08-13 | 2006-01-12 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体 |
KR101050680B1 (ko) * | 2002-11-02 | 2011-07-21 | 사노피-아벤티스 도이칠란트 게엠베하 | 콜라게네이즈의 선택적인 억제를 위한 신규한피리미딘-4,6-디카복스아미드 |
US20040142950A1 (en) * | 2003-01-17 | 2004-07-22 | Bunker Amy Mae | Amide and ester matrix metalloproteinase inhibitors |
WO2005046683A1 (fr) | 2003-10-07 | 2005-05-26 | Renovis, Inc. | Derives d'amide utilises comme ligands du canal ionique et compositions pharmaceutiques et methodes d'utilisation de ces derives |
US20060247231A1 (en) * | 2003-12-18 | 2006-11-02 | Warner-Lambert Company Llc | Amide and ester matrix metalloproteinase inhibitors |
KR100904360B1 (ko) | 2004-01-28 | 2009-06-23 | 미쓰이 가가쿠 가부시키가이샤 | 아미드 유도체 및 그 제조 방법 및 그의 살충제로서의 사용방법 |
US7576099B2 (en) | 2005-02-28 | 2009-08-18 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
WO2008002671A2 (fr) * | 2006-06-29 | 2008-01-03 | Alantos Pharmaceuticals Holding, Inc. | Inhibiteurs des métalloprotéases |
WO2008112164A2 (fr) | 2007-03-08 | 2008-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Modulateurs de l'aldéhyde déshydrogénase-2 mitochondrial, et leurs procédés d'utilisation |
JP2012502048A (ja) * | 2008-09-08 | 2012-01-26 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法 |
JP5657201B2 (ja) * | 2008-09-30 | 2015-01-21 | サンメディカル株式会社 | 酵素阻害作用または酵素阻害作用と抗菌作用とを有する歯科用組成物 |
KR20110082180A (ko) | 2008-10-28 | 2011-07-18 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 알데히드 탈수소효소의 조절자 및 그것의 사용방법 |
TWI405565B (zh) * | 2009-04-01 | 2013-08-21 | Colgate Palmolive Co | 口腔用組成物之抗-骨質流失及抗-牙周附連喪失之功效 |
GB201021103D0 (en) * | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | New compounds for the treatment of neurodegenerative diseases |
WO2012149106A1 (fr) | 2011-04-29 | 2012-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions et procédés d'augmentation de la prolifération de cellules souches salivaires adultes |
JP6410790B2 (ja) | 2013-03-14 | 2018-10-24 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ミトコンドリアアルデヒドデヒドロゲナーゼ−2調節因子およびその使用方法 |
EP3464242A1 (fr) * | 2016-05-24 | 2019-04-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Dérivés de pyridine dicarboxamide utilisés comme inhibiteurs de bromodomaine |
GB201703282D0 (en) * | 2017-03-01 | 2017-04-12 | Glaxosmithkline Intellectual Property (No 2) Ltd | Compounds |
GB201908453D0 (en) * | 2019-06-12 | 2019-07-24 | Enterprise Therapeutics Ltd | Compounds for treating respiratory disease |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1149356B (de) * | 1955-03-24 | 1963-05-30 | Bayer Ag | Verfahren zur Herstellung von N-substituierten Thiosaeureamiden |
US4971986A (en) * | 1988-03-25 | 1990-11-20 | Ciba-Geigy Corporation | Arylhydrazones useful as SAMDC inhibitors |
US5219847A (en) * | 1989-06-12 | 1993-06-15 | Shiseido Company, Ltd. | Antipruritic composition |
US5425289A (en) * | 1993-10-21 | 1995-06-20 | Snap-On Incorporated | Bung tool |
DE3924093A1 (de) * | 1989-07-20 | 1991-02-07 | Hoechst Ag | N,n'-bis(alkoxy-alkyl)-pyridin-2,4-dicarbonsaeurediamide, verfahren zu deren herstellung sowie deren verwendung |
DE3931432A1 (de) * | 1989-09-21 | 1991-04-04 | Hoechst Ag | Pyrimidin-4,6-dicarbonsaeurediamide, verfahren zu deren herstellung sowie verwendung derselben sowie arzneimittel auf basis dieser verbindungen |
DE4020570A1 (de) * | 1990-06-28 | 1992-01-02 | Hoechst Ag | 2,4- und 2,5-substituierte pyridin-n-oxide, verfahren zu deren herstellung sowie deren verwendung |
US5260323A (en) * | 1990-06-28 | 1993-11-09 | Hoechst Aktiengesellschaft | 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use |
US5716965A (en) * | 1991-05-22 | 1998-02-10 | Pfizer Inc. | Substituted 3-aminoquinuclidines |
RU2092486C1 (ru) * | 1991-05-22 | 1997-10-10 | Пфайзер Инк. | Замещенные 3-аминохинуклидины |
EP0541042A1 (fr) | 1991-11-05 | 1993-05-12 | Hoechst Aktiengesellschaft | Dérivés d'acide pyridine 2,4- et 2,5-dicarboxyliques, leur procédé de préparation et leur utilisation comme médicaments |
US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
JP2001504462A (ja) * | 1996-11-12 | 2001-04-03 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | ホスホジエステラーゼ阻害剤としての(2,3―ジヒドロベンゾフラニル)―チアゾール |
IL128545A0 (en) | 1996-12-09 | 2000-01-31 | Warner Lambert Co | Method for treating and preventing heart failure and ventricular dilatation |
JPH11199512A (ja) | 1997-10-24 | 1999-07-27 | Pfizer Prod Inc | 変形性関節症および他のmmp媒介疾患の治療のためのmmp−13選択的阻害剤の使用 |
UA59453C2 (uk) | 1998-08-12 | 2003-09-15 | Пфайзер Продактс Інк. | Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ |
US6307049B1 (en) * | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
US6300341B1 (en) * | 1998-09-30 | 2001-10-09 | The Procter & Gamble Co. | 2-substituted heterocyclic sulfonamides |
HUP0200705A3 (en) * | 1999-03-31 | 2002-12-28 | Basf Ag | Herbicidal pyridine-2,3-dicarboxylic acid diamides and use thereof |
PA8498701A1 (es) | 1999-08-12 | 2002-08-26 | Pfizer Prod Inc | Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas |
US6307490B1 (en) * | 1999-09-30 | 2001-10-23 | The Engineering Consortium, Inc. | Digital to analog converter trim apparatus and method |
US6934639B1 (en) | 2000-02-25 | 2005-08-23 | Wyeth | Methods for designing agents that interact with MMP-13 |
EP1138680A1 (fr) | 2000-03-29 | 2001-10-04 | Pfizer Products Inc. | Acides gem-substitués alpha-sulfonylamino hydroxamiques comme inhibiteurs de métalloprotease |
US6916846B2 (en) * | 2000-05-12 | 2005-07-12 | Merck & Co. Inc. | Coumermycin analogs as chemical dimerizers of chimeric proteins |
EP1332136A2 (fr) | 2000-10-26 | 2003-08-06 | Pfizer Products Inc. | Inhibiteurs de la pyrimidine-2,4,6-trione metalloproteinase |
HUP0301577A3 (en) | 2000-10-26 | 2006-02-28 | Pfizer Prod Inc | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors, pharmaceutical compositions containing them and their use |
DOP2002000333A (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz |
PA8539301A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
DOP2002000328A (es) * | 2001-02-14 | 2003-08-30 | Warner Lambert Co | Pirimidinas inhibidoras de metaloproteinasas de matriz |
US6924276B2 (en) * | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
DE10160357A1 (de) | 2001-12-08 | 2003-06-18 | Aventis Pharma Gmbh | Verwendung von Pyridin-2,4-dicarbonsäurediamiden und Pyrimidin-4,6-dicarbonsäurediamiden zur selektiven Inhibierung von Kollagenasen |
US6933298B2 (en) * | 2001-12-08 | 2005-08-23 | Aventis Pharma Deutschland Gmbh | Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases |
US20050004111A1 (en) * | 2003-01-03 | 2005-01-06 | Aventis Pharma Deutschland Gmbh | Selective MMP-13 inhibitors |
-
2002
- 2002-01-24 DO DO2002000332A patent/DOP2002000332A/es unknown
- 2002-02-01 PA PA20028538201A patent/PA8538201A1/es unknown
- 2002-02-04 AP APAP/P/2003/002840A patent/AP2003002840A0/en unknown
- 2002-02-04 CZ CZ20032143A patent/CZ20032143A3/cs unknown
- 2002-02-04 DE DE60219286T patent/DE60219286T2/de not_active Expired - Lifetime
- 2002-02-04 CA CA002434982A patent/CA2434982A1/fr not_active Abandoned
- 2002-02-04 KR KR10-2003-7010682A patent/KR20030075196A/ko not_active Application Discontinuation
- 2002-02-04 SK SK1002-2003A patent/SK10022003A3/sk unknown
- 2002-02-04 OA OA1200300180A patent/OA12544A/en unknown
- 2002-02-04 PL PL02365098A patent/PL365098A1/xx not_active Application Discontinuation
- 2002-02-04 MX MXPA03006204A patent/MXPA03006204A/es active IP Right Grant
- 2002-02-04 HU HU0303152A patent/HUP0303152A2/hu unknown
- 2002-02-04 WO PCT/IB2002/000345 patent/WO2002064568A1/fr active IP Right Grant
- 2002-02-04 BR BR0207863-5A patent/BR0207863A/pt not_active IP Right Cessation
- 2002-02-04 EP EP02716263A patent/EP1362033B1/fr not_active Expired - Lifetime
- 2002-02-04 IL IL15691202A patent/IL156912A0/xx unknown
- 2002-02-04 JP JP2002564501A patent/JP4249981B2/ja not_active Expired - Fee Related
- 2002-02-04 EE EEP200300391A patent/EE200300391A/xx unknown
- 2002-02-04 EA EA200300763A patent/EA200300763A1/ru unknown
- 2002-02-04 GT GT200200014A patent/GT200200014A/es unknown
- 2002-02-04 ES ES02716263T patent/ES2283540T3/es not_active Expired - Lifetime
- 2002-02-04 AT AT02716263T patent/ATE358667T1/de not_active IP Right Cessation
- 2002-02-04 CN CNA028049454A patent/CN1537101A/zh active Pending
- 2002-02-08 US US10/071,073 patent/US6881743B2/en not_active Expired - Fee Related
- 2002-02-11 HN HN2002000028A patent/HN2002000028A/es unknown
- 2002-02-11 HN HN2002000025A patent/HN2002000025A/es unknown
- 2002-02-13 TN TNTNSN02012A patent/TNSN02012A1/fr unknown
- 2002-02-13 UY UY27167A patent/UY27167A1/es not_active Application Discontinuation
- 2002-02-13 PE PE2002000119A patent/PE20020995A1/es not_active Application Discontinuation
- 2002-02-13 AR ARP020100478A patent/AR035936A1/es unknown
-
2003
- 2003-07-10 IS IS6871A patent/IS6871A/is unknown
- 2003-07-16 EC EC2003004691A patent/ECSP034691A/es unknown
- 2003-08-05 CR CR7048A patent/CR7048A/es not_active Application Discontinuation
- 2003-08-05 ZA ZA200306041A patent/ZA200306041B/xx unknown
- 2003-08-05 MA MA27263A patent/MA26989A1/fr unknown
- 2003-08-12 NO NO20033570A patent/NO20033570L/no not_active Application Discontinuation
- 2003-08-13 BG BG108089A patent/BG108089A/xx unknown
-
2004
- 2004-05-10 US US10/842,863 patent/US7015237B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA26989A1 (fr) | Derives de pyridine inhibiteurs de metalloproteinases de matrice | |
BR0207209A (pt) | Inibidores de metaloproteinase de matriz de pirimidina | |
MA27573A1 (fr) | Sinomenine et derives de sinomenine, synthese et utilisation. | |
MA26877A1 (fr) | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant | |
TN2010000053A1 (fr) | Derives de bi cyclolactames substitues | |
CA2203618A1 (fr) | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
MA26957A1 (fr) | Spiro-pyrimidine-2,4,6-triones inhibitrices de metalloproteinases. | |
HUP0204474A2 (hu) | 1H-imidazopiridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
DK0620216T3 (da) | Benzamidderivater og deres anvendelse som vasopressinantagonister | |
MA32164B1 (fr) | Derive heterocyclique fusionne et son utilisation | |
MA30524B1 (fr) | Agent de lutte antiparasite contenant un nouveau derive de pyridyl-methanamine ou un sel de celui-ci | |
MA27183A1 (fr) | Composes oxo-azabicycliques | |
BRPI0511581A (pt) | derivados de tetrahidroisoquinolilsulfonamidas, sua preparação e sua utilização em terapêutica | |
AR054102A1 (es) | Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas | |
ES2149777T3 (es) | Derivados de triazol que tienen actividad antifungica. | |
MA27712A1 (fr) | Triazoles utiles en therapeutique | |
MA29559B1 (fr) | Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique | |
MA27104A1 (fr) | Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
TNSN07043A1 (fr) | Oxazolidinones contenant des oxindoles, servant d'agents antibacteriens | |
HUP0402081A2 (hu) | NK-2 antagonista hatású egyenes láncú bázisos vegyületek és ezeket tartalmazó gyógyszerészeti készítmények | |
MA27167A1 (fr) | ACIDES 3-(IMIDAZOLYL)-2-ALKOXYPROPANOiQUES SERVANT D'INHIBITEURS DE TAFIa. | |
FI956300A0 (fi) | Pyridatsinonijohdannaisia | |
NO20070421L (no) | Radiosensitiviserende middel | |
TNSN06185A1 (fr) | Derives de benzenesulfonylamino-pyridine-2-yle et composes apparentes servant d'inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase de type 1 (11-beta-hsd-1) pour le traitement du diabete et de l'obesite | |
MA27091A1 (fr) | Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |